Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.

Gupta R, Bollyky TJ, Cohen M, Ross JS, Kesselheim AS.

BMJ. 2018 Mar 19;360:k831. doi: 10.1136/bmj.k831.

2.

Formularies, costs, and quality of care: Limiting formularies is not harmful to patients.

Jones WN.

Neurol Clin Pract. 2013 Feb;3(1):75-77. doi: 10.1212/CPJ.0b013e318283ff3e. No abstract available.

3.

Generic-reference and generic-generic bioequivalence of forty-two, randomly-selected, on-market generic products of fourteen immediate-release oral drugs.

Hammami MM, De Padua SJS, Hussein R, Al Gaai E, Khodr NA, Al-Swayeh R, Alvi SN, Binhashim N.

BMC Pharmacol Toxicol. 2017 Dec 8;18(1):78. doi: 10.1186/s40360-017-0182-1.

4.

Assessment of health seeking behaviour and self-medication among general public in the state of Penang, Malaysia.

Dawood OT, Hassali MA, Saleem F, Ibrahim IR, Abdulameer AH, Jasim HH.

Pharm Pract (Granada). 2017 Jul-Sep;15(3):991. doi: 10.18549/PharmPract.2017.03.991. Epub 2017 Aug 16.

5.

Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending.

Wouters OJ, Kanavos PG, McKEE M.

Milbank Q. 2017 Sep;95(3):554-601. doi: 10.1111/1468-0009.12279.

PMID:
28895227
6.

Safety of switching from brand-name to generic levetiracetam in patients with epilepsy.

Bosak M, Słowik A, Turaj W.

Drug Des Devel Ther. 2017 Aug 3;11:2287-2291. doi: 10.2147/DDDT.S138270. eCollection 2017.

7.

Medicine shortages in Fiji: A qualitative exploration of stakeholders' views.

Walker J, Chaar BB, Vera N, Pillai AS, Lim JS, Bero L, Moles RJ.

PLoS One. 2017 Jun 5;12(6):e0178429. doi: 10.1371/journal.pone.0178429. eCollection 2017.

8.

Drug Brand Response and Its Impact on Compliance and Efficacy in Depression Patients.

Li M, Cai J, Zhang P, Fei C, Xu F.

Front Pharmacol. 2017 Jan 10;7:540. doi: 10.3389/fphar.2016.00540. eCollection 2016.

9.

Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?

Godman B, Shrank W, Wettermark B, Andersen M, Bishop I, Burkhardt T, Garuolienè K, Kalaba M, Laius O, Joppi R, Sermet C, Schwabe U, Teixeira I, Tulunay FC, Wendykowska K, Zara C, Gustafsson LL.

Pharmaceuticals (Basel). 2010 Aug 5;3(8):2470-2494. Review.

10.

Switching generic antiepileptic drug manufacturer not linked to seizures: A case-crossover study.

Kesselheim AS, Bykov K, Gagne JJ, Wang SV, Choudhry NK.

Neurology. 2016 Oct 25;87(17):1796-1801. Epub 2016 Sep 28.

11.

Variations in Patients' Perceptions and Use of Generic Drugs: Results of a National Survey.

Kesselheim AS, Gagne JJ, Franklin JM, Eddings W, Fulchino LA, Avorn J, Campbell EG.

J Gen Intern Med. 2016 Jun;31(6):609-14. doi: 10.1007/s11606-016-3612-7. Epub 2016 Feb 16.

12.

The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?

Sarpatwari A, Kesselheim AS.

PLoS Med. 2016 Feb 9;13(2):e1001955. doi: 10.1371/journal.pmed.1001955. eCollection 2016 Feb. Review. No abstract available.

13.

Generic versus brand-name drugs used in cardiovascular diseases.

Manzoli L, Flacco ME, Boccia S, D'Andrea E, Panic N, Marzuillo C, Siliquini R, Ricciardi W, Villari P, Ioannidis JP.

Eur J Epidemiol. 2016 Apr;31(4):351-68. doi: 10.1007/s10654-015-0104-8. Epub 2015 Nov 30. Review.

14.

A comparison of the intrasubject variation in drug exposure between generic and brand-name drugs: a retrospective analysis of replicate design trials.

Yu Y, Teerenstra S, Neef C, Burger D, Maliepaard M.

Br J Clin Pharmacol. 2016 Apr;81(4):667-78. doi: 10.1111/bcp.12828. Epub 2016 Jan 15.

15.

Bias within economic evaluations - the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug.

Guertin JR, Mitchell D, Ali F, LeLorier J.

Clinicoecon Outcomes Res. 2015 Oct 6;7:497-503. doi: 10.2147/CEOR.S90386. eCollection 2015.

16.

Generic drugs: Review and experiences from South India.

Mathew P.

J Family Med Prim Care. 2015 Jul-Sep;4(3):319-23. doi: 10.4103/2249-4863.161305.

17.
18.

Potential Clinical and Economic Impact of Switching Branded Medications to Generics.

Straka RJ, Keohane DJ, Liu LZ.

Am J Ther. 2017 May;24(3):e278-e289. doi: 10.1097/MJT.0000000000000282. Review.

19.

The Impact of Generic Substitution on Health and Economic Outcomes: A Systematic Review.

Gothe H, Schall I, Saverno K, Mitrovic M, Luzak A, Brixner D, Siebert U.

Appl Health Econ Health Policy. 2015 Aug;13 Suppl 1:S21-33. doi: 10.1007/s40258-014-0147-0. Review.

20.

Paying physicians to prescribe generic drugs and follow-on biologics in the United States.

Sarpatwari A, Choudhry NK, Avorn J, Kesselheim AS.

PLoS Med. 2015 Mar 17;12(3):e1001802. doi: 10.1371/journal.pmed.1001802. eCollection 2015 Mar.

Supplemental Content

Support Center